BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 14, 2025
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

SK Biocience-Novavax signing agreement

Settling debt, strengthening ties: Novavax hands 6.45% stake to SK Bioscience

Aug. 9, 2023
By Marian (YoonJee) Chu
Novavax Inc. has signed off 6.5 million shares to SK Bioscience Co. Ltd. for an $85 million equity investment from the South Korean pharmaceutical firm, which also wrote off some of Novavax’s manufacturing liabilities, as part of their continuing vaccine alliance. Seongnam-si, South Korea-based SK Bioscience purchased Novavax shares at $13 each, reflecting a 59% premium over the 90-day trading value, to gain a 6.45% stake in the Gaithersburg, Md.-based mRNA vaccine company, an SK Bioscience spokesperson confirmed to BioWorld.
Read More

In the clinic for Aug. 9, 2023

Aug. 9, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Algernon, Bioxytran, Bright Minds, Cocrystal, Halia, Lexicon, Maia, Meissa, Monopar, Nasus, Nervgen, Novo Nordisk, Oculis, Palatin, Praxis, Telix, Urogen, Viracta.
Read More
Infection

Simcere Zaiming Pharmaceutical defines 3CL protease inhibitor for COVID-19 infections

Aug. 9, 2023
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of respiratory tract infections.
Read More
Creative rendition of SARS-CoV-2 virus particles.
Infection

Infex Therapeutics nominates new lead pan-coronavirus antiviral candidate

Aug. 9, 2023
Researchers from Infex Therapeutics Ltd. have announced the nomination of a clinical candidate for its in-house developed COV-X program. The novel first-in-class small molecule is an oral pan-coronavirus papain-like protease (PLpro) inhibitor, which was selected based on preclinical data that demonstrated in vivo efficacy of the candidate a murine model of SARS-CoV-2.
Read More
Vaccine vial and syringe

New UK vaccine center targeting pandemic-potential pathogens

Aug. 8, 2023
Building on capabilities developed during the COVID-19 pandemic, the U.K. Health Security Agency’s Vaccine Development and Evaluation Centre hit the ground running.
Read More

In the clinic for Aug. 8, 2023

Aug. 8, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aiviva, Apogee, Bavarian Nordic, Halia, Humanigen, Nektar, Passage, Praxis, Tonix, Vistagen.
Read More

Other news to note for Aug. 8, 2023

Aug. 8, 2023
Additional early-stage research and drug discovery news in brief, from: Imunon, Marker Therapeutic.
Read More

Other news to note for August 4, 2023

Aug. 4, 2023
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Angiodynamics, Body Vision, Cue, Femasys, Hemosonics, Invo, Kral Medical, Prism Technologies, Paragon Care, Shockwave Medical, Tandem.
Read More

Regulatory actions for Aug. 3, 2023

Aug. 3, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Hipra, M8, Molecular Targeting, Satellos.
Read More

In the clinic for Aug. 3, 2023

Aug. 3, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cybin, Enlivex, Ideaya, Immunis, India Globalization, Inimmune, Oculis, Theriva.
Read More
Previous 1 2 … 29 30 31 32 33 34 35 36 37 … 548 549 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing